Mirati Therapeutics Inc (DELISTED) (MRTX:DL)
58.70
0.00 (0.00%)
USD |
NASDAQ |
Jan 23, 16:00
Mirati Therapeutics Research and Development Expense (Quarterly): 114.77M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 114.77M |
| June 30, 2023 | 124.19M |
| March 31, 2023 | 126.68M |
| December 31, 2022 | 141.24M |
| September 30, 2022 | 131.08M |
| June 30, 2022 | 128.34M |
| March 31, 2022 | 130.98M |
| December 31, 2021 | 153.84M |
| September 30, 2021 | 116.11M |
| June 30, 2021 | 134.58M |
| March 31, 2021 | 104.07M |
| December 31, 2020 | 82.70M |
| September 30, 2020 | 79.85M |
| June 30, 2020 | 65.08M |
| March 31, 2020 | 71.71M |
| December 31, 2019 | 62.94M |
| September 30, 2019 | 47.36M |
| June 30, 2019 | 38.32M |
| March 31, 2019 | 34.24M |
| December 31, 2018 | 26.76M |
| September 30, 2018 | 23.63M |
| June 30, 2018 | 23.83M |
| March 31, 2018 | 19.66M |
| December 31, 2017 | 15.24M |
| September 30, 2017 | 13.48M |
| Date | Value |
|---|---|
| June 30, 2017 | 14.96M |
| March 31, 2017 | 14.40M |
| December 31, 2016 | 15.95M |
| September 30, 2016 | 16.11M |
| June 30, 2016 | 18.44M |
| March 31, 2016 | 17.99M |
| December 31, 2015 | 14.91M |
| September 30, 2015 | 14.56M |
| June 30, 2015 | 11.28M |
| March 31, 2015 | 8.207M |
| December 31, 2014 | 7.076M |
| September 30, 2014 | 6.886M |
| June 30, 2014 | 7.149M |
| March 31, 2014 | 4.96M |
| December 31, 2013 | 4.32M |
| September 30, 2013 | 5.492M |
| June 30, 2013 | 4.51M |
| March 31, 2013 | 5.475M |
| December 31, 2012 | 4.976M |
| September 30, 2012 | 4.249M |
| June 30, 2012 | 3.652M |
| March 31, 2012 | 2.204M |
| December 31, 2011 | 3.153M |
| September 30, 2011 | 2.012M |
| June 30, 2011 | 1.852M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
38.32M
Minimum
Jun 2019
153.84M
Maximum
Dec 2021
102.99M
Average
115.44M
Median
Research and Development Expense (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | 2.695B |
| Karuna Therapeutics Inc (DELISTED) | 82.19M |
| Puma Biotechnology Inc | 13.59M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |